LIT vs XBI
Global X Lithium & Battery Tech ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.75% for LIT.
- • LIT pays a higher dividend yield (0.36%).
Side-by-side metrics
| Metric | LIT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.36% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $2.13B | $8.30B |
YTD return | 41.10% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.35 | 1.09 |
P/E ratio | 26.96 | — |
Last price | $89.35 | $133.66 |
Inception | — | — |
Issuer | Global X | State Street |
LIT top holdings
| RIO | Rio Tinto PLC ADR | 20.21% |
| 006400.KS | Samsung SDI Co Ltd | 7.15% |
| ALB | Albemarle Corp | 7.12% |
| 6752.T | Panasonic Holdings Corp | 4.68% |
| 002460.SZ | Ganfeng Lithium Group Co Ltd Class A | 4.16% |
| PLS.AX | PLS Group Ltd | 4.15% |
| SQM | Sociedad Quimica Y Minera De Chile SA ADR | 4.06% |
| 002371.SZ | NAURA Technology Group Co Ltd Class A | 3.84% |
| 002466.SZ | Tianqi Lithium Corp Class A | 3.51% |
| 300750.SZ | Contemporary Amperex Technology Co Ltd Class A | 3.49% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About LIT
LIT (Global X Lithium & Battery Tech ETF) is Full lithium cycle from mining to battery production. Managed by Global X, the fund carries $2.1B in assets under management, an expense ratio of 0.75%, a dividend yield of 0.36%. Its largest holding is Rio Tinto PLC ADR (RIO), which represents 20.2% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 7.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.